MedPath

VINORELBINE, CARBOPLATIN AND TRASTUZUMAB IN ADVANCED HER-2 POSITIVE BREAST CANCER. A PHASE 2 STUDY - VinCaT

Conditions
BREAST CANCER
MedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastatic
Registration Number
EUCTR2006-003994-28-IT
Lead Sponsor
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

? Histologically confirmed HER2-positive (immunohistochemistry [IHC 3+] or fluorescence or chromogenic in situ hybridization [FISH+, CISH+]) breast cancer

? Stage IV

? Age ? 18 and < 75 years

? ECOG Performance Status 0-2

? Life expectancy >3 months

? None or at most one treatment for metastatic disease

? Neutrophils ? 2 x 109/L and Platelets ?100 x 109/L

? Total bilirubin, ASAT (GOT) and/or ALAT (GPT) ?1.25 time the upper-normal limits (UNL) of the Institutional normal values

? Adequate renal function (serum creatinine < 1.5 UNL)

? Normal Left Ventricular Ejection Fraction (LVEF) >50% (evaluated by ultrasonography).

? Measurable or evaluable disease

? Signed informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

? More than one prior chemotherapy for metastatic disease

? Previous chemotherapy with vinorelbine or carboplatin (as adjuvant therapy or for metastatic disease)

? Trastuzumab treatment for metastatic disease (an adjuvant therapy with trastuzumab is allowed)

? History of prior malignancy in the last 5 years (other than non-melanoma skin cancer or excised cervical carcinoma in situ).

? Other serious illness or medical condition

? Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction, uncontrolled high risk hypertension or arrhythmia

? History of significant neurological or psychiatric disorders including dementia or seizures

? Active infection

? Geographic inaccessibility for treatment and follow up

? Pregnant or lactating women

? Male

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath